Floatz logo

Certepetide

Gallbladder Cancer

Lisata Therapeutics, Inc.protein_peptidePhase 2Active
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
95/ 100

Competitive context

29 Active assets in the Gallbladder Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Lisata Therapeutics, Inc.
Phase 2BBB
Capecitabine
Merck Sharp & Dohme LLC
Phase 3BB
Eloxatin
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Docetaxel
Merck Sharp & Dohme LLC
Phase 2BB
Sevoflurane
Tokyo Medical and Dental University
Phase 4BB

View all 50 →

Same molecule, other indications

Certepetide is also rated in:

pancreatic ductal adenocarcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
malignant pancreatic neoplasmDormant
CCC
Indicative ·
51 / 100
View asset →
gallbladder carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →